Altimmune, Inc. (ALT) Q4 FY25 Earnings Call

Management targets Phase III initiation this year, supported by approximately $340 million cash and runway into 2028.

Q4 FY25 results, source: company transcript and SEC filings
QuarterQ4 FY25
Call date2026-03-05
Length61 minutes
EPS$-0.27
EPS consensus$-0.25
Revenue$5000.00

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q2 FY26

All ALT earnings ยท Back to ALT overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.